Is the Mesoblast limited share price about to blast off?

Does the positive trial update this morning make Mesoblast limited (ASX:MSB) shares a buy?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Regenerative medicine hopeful Mesoblast limited (ASX: MSB) reported to the market this morning that it had completed "Successful Interim Analysis in Phase 3 Heart Failure Trial".

Specifically, "the Phase 3 trial… was successful in the pre-specified interim futility analysis of the efficacy endpoint in the trial's first 270 patients." The Independent Data Monitoring Committee (IDMC) stated that they had no safety concerns and recommended that the trial proceed as planned.

Excellent. I love a good futility analysis of the efficacy endpoint, and it is good to know that the treatment won't kill the patients.

So…?

In plain English, this means simply that the interim results from the first 270 patients have been examined. So far, the trial is not 'futile' – which is to say, it is not obviously a waste of time and that there is a 'reasonable' chance of a positive outcome. That is a necessary check to make from a research standpoint, but in a practical sense, shareholders already knew this from the Phase 2 results, which were positive and resulted in the treatment advancing to Phase 3 trials.

I would not get unduly excited at this point. This is a 'blind' trial, which is to say that Mesoblast itself has not seen the interim results. The company has no idea whether the trial will be successful, although a recommendation from an independent expert to continue the research is encouraging. Mesoblast will now recruit another 330 patients to meet its planned complement of 600, and the trial itself will run until February 2018, with study completion in February 2019.

The bottom line

Mesoblast is a good example of why I encourage readers to be wary of biotech stocks. That is not a stab against the company, which does good research and has a promising product in a growing market. It is simply a reflection that unless you are willing to learn about the jargon and the science behind the trial, you are at a significant disadvantage.

As to whether the company itself is a buy, well, it is loss-making and I will be waiting to see how the company's cash at bank and expenditure looks in August before considering a purchase.

Motley Fool contributor Sean O'Neill has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »